SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Poulsen P.) ;lar1:(uu)"

Sökning: WFRF:(Poulsen P.) > Uppsala universitet

  • Resultat 1-10 av 179
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
10.
  • Aad, G, et al. (författare)
  • Measurements of the Higgs boson inclusive and differential fiducial cross sections in the 4 ℓ decay channel at √s = 13 TeV
  • 2020
  • Ingår i: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044 .- 1434-6052. ; 80:10
  • Tidskriftsartikel (refereegranskat)abstract
    • Inclusive and differential fiducial cross sections of the Higgs boson are measured in the H→ ZZ∗→ 4 ℓ (ℓ= e, μ) decay channel. The results are based on proton−proton collision data produced at the Large Hadron Collider at a centre-of-mass energy of 13 TeV and recorded by the ATLAS detector from 2015 to 2018, equivalent to an integrated luminosity of 139 fb - 1. The inclusive fiducial cross section for the H→ ZZ∗→ 4 ℓ process is measured to be σfid= 3.28 ± 0.32 fb, in agreement with the Standard Model prediction of σfid , SM= 3.41 ± 0.18 fb. Differential fiducial cross sections are measured for a variety of observables which are sensitive to the production and decay of the Higgs boson. All measurements are in agreement with the Standard Model predictions. The results are used to constrain anomalous Higgs boson interactions with Standard Model particles. © 2020, The Author(s).
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 179
Typ av publikation
tidskriftsartikel (179)
Typ av innehåll
refereegranskat (178)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Ellert, Mattias (163)
Brenner, Richard (162)
Ekelöf, Tord (162)
Strandberg, Jonas (155)
Ripellino, Giulia (152)
Zwalinski, L. (151)
visa fler...
Moa, Torbjörn (148)
Clement, Christophe (148)
Milstead, David A. (148)
Sjölin, Jörgen (148)
Hellman, Sten (147)
Shaikh, Nabila W. (147)
Wallängen, Veronica (147)
Sidebo, P. Edvin (144)
Bokan, Petar (142)
Bocchetta, Simona (139)
Poulsen, Trine (139)
Åkesson, Torsten (138)
Doglioni, Caterina (138)
Hedberg, Vincent (138)
Jarlskog, Göran (138)
Lytken, Else (138)
Mjörnmark, Ulf (138)
Smirnova, Oxana (138)
Jon-And, Kerstin (136)
Kalderon, Charles (134)
Ughetto, Michaël (134)
Pöttgen, Ruth (132)
Silverstein, Samuel ... (132)
Gradin, P.O. Joakim (131)
Bergeås Kuutmann, El ... (128)
Carney, Rebecca M. D ... (127)
Mankinen, Katja (124)
Bertoli, Gabriele (124)
Ferrari, Arnaud, 197 ... (122)
Valdés Santurio, Edu ... (122)
Molander, Simon (119)
Lund-Jensen, Bengt (116)
Kellermann, Edgar (113)
Gellerstedt, Karl (113)
Kastanas, Konstatino ... (110)
Isacson, Max (100)
Viazlo, Oleksandr (92)
Bessidskaia Bylund, ... (92)
Öhman, Henrik (89)
Sales De Bruin, Pedr ... (88)
Konya, Balazs (85)
Bohm, Christian (84)
Aad, G (80)
Abulaiti, Yiming (77)
visa färre...
Lärosäte
Uppsala universitet  (179)Ta bort avgränsningen
Lunds universitet (164)
Kungliga Tekniska Högskolan (156)
Stockholms universitet (151)
Karolinska Institutet (11)
Göteborgs universitet (1)
visa fler...
Linköpings universitet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (179)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (166)
Medicin och hälsovetenskap (11)
Teknik (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy